| Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies F Crea, S Nobili, E Paolicchi, G Perrone, C Napoli, I Landini, R Danesi, ... Drug Resistance Updates 14 (6), 280-296, 2011 | 156 | 2011 |
| Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells A Avan, F Crea, E Paolicchi, N Funel, E Galvani, VE Marquez, ... Molecular cancer therapeutics 11 (8), 1735-1746, 2012 | 122 | 2012 |
| Polycomb genes and cancer: time for clinical application? F Crea, E Paolicchi, VE Marquez, R Danesi Critical reviews in oncology/hematology 83 (2), 184-193, 2012 | 101 | 2012 |
| Targeting hypoxic response for cancer therapy E Paolicchi, F Gemignani, M Krstic-Demonacos, S Dedhar, L Mutti, ... Oncotarget 7 (12), 13464, 2016 | 99 | 2016 |
| Histone lysine demethylases in breast cancer E Paolicchi, F Crea, WL Farrar, JE Green, R Danesi Critical reviews in oncology/hematology 86 (2), 97-103, 2013 | 61 | 2013 |
| An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients F Crea, L Fornaro, E Paolicchi, G Masi, P Frumento, F Loupakis, ... Annals of oncology 23 (5), 1207-1213, 2012 | 60 | 2012 |
| Novel genome-wide association study–based candidate loci for differentiated thyroid cancer risk G Figlioli, A Köhler, B Chen, R Elisei, C Romei, M Cipollini, A Cristaudo, ... The Journal of Clinical Endocrinology & Metabolism 99 (10), E2084-E2092, 2014 | 55 | 2014 |
| An aromatase polymorphism (g. 132810C> T) predicts risk of bisphosphonate-related osteonecrosis of the jaw FL Ferla, E Paolicchi, F Crea, S Cei, F Graziani, M Gabriele, R Danesi Biomarkers in Medicine 6 (2), 201-209, 2012 | 32 | 2012 |
| Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk G Figlioli, B Chen, R Elisei, C Romei, C Campo, M Cipollini, A Cristaudo, ... Scientific reports 5 (1), 8922, 2015 | 29 | 2015 |
| DNA repair and cancer in colon and rectum: Novel players in genetic susceptibility B Pardini, A Corrado, E Paolicchi, G Cugliari, SI Berndt, S Bezieau, ... International journal of cancer 146 (2), 363-372, 2020 | 24 | 2020 |
| A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma E Paolicchi, P Pacetti, E Giovannetti, A Mambrini, M Orlandi, F Crea, ... Oncology letters 6 (5), 1487-1491, 2013 | 22 | 2013 |
| Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer L Fornaro, P Faviana, V De Gregorio, C Vivaldi, E Paolicchi, G Masi, ... BMC cancer 15, 1-6, 2015 | 11 | 2015 |
| Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals C De Santi, P Pucci, A Bonotti, O Melaiu, M Cipollini, R Silvestri, ... Occupational and Environmental Medicine 74 (6), 457-464, 2017 | 9 | 2017 |
| A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients M Maftouh, A Avan, N Funel, E Paolicchi, E Vasile, P Pacetti, V Vaccaro, ... Pharmacogenomics 15 (5), 609-618, 2014 | 8 | 2014 |
| EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle L Fornaro, F Crea, G Masi, E Paolicchi, F Loupakis, F Graziano, ... Annals of oncology 23 (5), 1370-1371, 2012 | 8 | 2012 |
| Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma I Dell’Anno, SA Martin, M Barbarino, A Melani, R Silvestri, M Bottaro, ... Investigational new drugs 39, 644-657, 2021 | 7 | 2021 |
| Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients E Paolicchi, C Vivaldi, V De Gregorio, F Crea, L Fornaro, G Masi, ... Oncology 91 (5), 283-288, 2016 | 6 | 2016 |
| EZH2 single nucleotide variants (SNVs): Diagnostic and prognostic role in 10 solid tumor types E Paolicchi, L Fornaro, S Landi, S Rigas, F Crea Epigenomes 1 (3), 18, 2017 | 1 | 2017 |
| Front & Back Matter C Vivaldi, L Fornaro, G Masi, A Falcone, E Paolicchi, V De Gregorio, ... Oncology 91 (5), 2016 | | 2016 |
| Role of the estradiol in the development of papillary thyroid carcinoma in women E Paolicchi, G Figlioli, M Cipollini, K Hemminki, A Försti, S Landi, ... European Journal of Cancer 1 (61), S164-S165, 2016 | | 2016 |
Crea FrancescoProfessor of Cancer Pharmacology, The Open UniversityEmail yang diverifikasi di open.ac.uk
